Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

01-10-2007 | Case Report

Subconjunctival bevacizumab for corneal neovascularization

Authors: Mesut Erdurmus, Yuksel Totan

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 10/2007

Abstract

Objective

To report the efficacy of subconjunctival bevacizumab injection in patients with corneal neovascularization (NV).

Methods

This retrospective interventional case study included two eyes of two patients with corneal NV due to aqueous-deficient dry eye with filamentary keratitis in the first case, and corneal graft failure in the second case. Patients received a subconjunctival injection of 2.5 mg (0.1 ml) bevacizumab. Morphologic changes were investigated by slit-lamp biomicroscopy and corneal photography.

Results

Corneal NV was dramatically regressed a week after injection in the first case. In the second case, minor vessels were regressed while the major one did not. No infection or inflammation was observed. No relapse was seen within the follow-up of two to three months.

Conclusion

Subconjunctival injection of bevacizumab may offer an additional strategy for the treatment of corneal NV.

Abraham-Marin ML, Cortes-Luna CF, Alvarez-Rivera G, Hernandez-Rojas M, Quiroz-Mercado H, Morales-Canton V (2006) Intravitreal bevacizumab therapy for neovascular age-related macular degeneration: a pilot study. Graefe’s Arch Clin Exp Ophthalmol [Epub ahead of print]

Amano S, Rohan R, Kuroki M, Tolentino M, Adamis AP (1998) Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci 39:18–22PubMed

Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP, Noureddin BN (2006) Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 142:1–9PubMedCrossRef

Chang JH, Gabison EE, Kato T, Azar DT (2001) Corneal neovascularization. Curr Opin Ophthalmol 12:242–249PubMedCrossRef

Iliev ME, Domig D, Wolf-Schnurrbursch U, Wolf S, Sarra GM (2006) Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol 142:1054–1056PubMedCrossRef

Philipp W, Speicher L, Humpel C (2000) Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci 41:2514–2522PubMed

Wang Y, Fei D, Vanderlaan M, Song A (2004) Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 7:335–345PubMedCrossRef

Title: Subconjunctival bevacizumab for corneal neovascularization
Authors: Mesut Erdurmus
Yuksel Totan
Publication date: 01-10-2007
Publisher: Springer-Verlag
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 10/2007
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-007-0587-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Subconjunctival bevacizumab for corneal neovascularization

Abstract

Objective

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2007

Inner limiting membrane as membranous support in RPE sheet-transplantation

A novel mutation of the OPA1 gene in a Japanese patient with autosomal dominant optic atrophy

Inhibition of corneal angiogenesis by ascorbic acid in the rat model

Bilateral cystoid macular edema in a patient with chronic myeloid leukaemia under treatment with imanitib mesylate: report of an unusual side effect

Photodynamic therapy for recurrent hyphema after proton beam radiotherapy of iris melanoma

Long-term effects of radial optic neurotomy for central retinal vein occlusion consecutive interventional case series